BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics of inhaled salbutamol in patients with cystic fibrosis versus healthy young adults. 1987

N Vaisman, and G Koren, and D Goldstein, and G J Canny, and Y K Tan, and S Soldin, and P Pencharz
Department of Pediatrics, Hospital for Sick Children, University of Toronto, Ontario, Canada.

We studied the disposition of inhaled salbutamol in adolescents with cystic fibrosis (CF) and compared it with the pharmacokinetics of the drug given by the intravenous and inhaled routes in healthy adults. After inhalation of salbutamol, CF patients had a significantly larger area under the concentration-time curve derived from amounts of drug in the systemic circulation. The differences in serum concentration of salbutamol were not reflected in differences in change of heart rate. We conclude that the rate and extent of pulmonary absorption of inhaled salbutamol in patients with CF differ from those in healthy adults.

UI MeSH Term Description Entries
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000280 Administration, Inhalation The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract. Drug Administration, Inhalation,Drug Administration, Respiratory,Drug Aerosol Therapy,Inhalation Drug Administration,Inhalation of Drugs,Respiratory Drug Administration,Aerosol Drug Therapy,Aerosol Therapy, Drug,Drug Therapy, Aerosol,Inhalation Administration,Administration, Inhalation Drug,Administration, Respiratory Drug,Therapy, Aerosol Drug,Therapy, Drug Aerosol
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000420 Albuterol A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol. Salbutamol,2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol,Albuterol Sulfate,Proventil,Sultanol,Ventolin
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

N Vaisman, and G Koren, and D Goldstein, and G J Canny, and Y K Tan, and S Soldin, and P Pencharz
Pharmacokinetics of inhaled colistin in patients with cystic fibrosis.
February 2006, The Journal of antimicrobial chemotherapy,
N Vaisman, and G Koren, and D Goldstein, and G J Canny, and Y K Tan, and S Soldin, and P Pencharz
Comment on: pharmacokinetics of inhaled colistin in patients with cystic fibrosis.
July 2006, The Journal of antimicrobial chemotherapy,
N Vaisman, and G Koren, and D Goldstein, and G J Canny, and Y K Tan, and S Soldin, and P Pencharz
Pharmacokinetics of inhaled salbutamol in asthmatic patients.
October 1971, British journal of pharmacology,
N Vaisman, and G Koren, and D Goldstein, and G J Canny, and Y K Tan, and S Soldin, and P Pencharz
Population pharmacokinetics of inhaled tobramycin powder in cystic fibrosis patients.
February 2014, CPT: pharmacometrics & systems pharmacology,
N Vaisman, and G Koren, and D Goldstein, and G J Canny, and Y K Tan, and S Soldin, and P Pencharz
Ticarcillin/clavulanic acid pharmacokinetics in children and young adults with cystic fibrosis.
June 1985, The Journal of pediatrics,
N Vaisman, and G Koren, and D Goldstein, and G J Canny, and Y K Tan, and S Soldin, and P Pencharz
Pharmacokinetics of doxycycline in adults with cystic fibrosis.
January 2012, Antimicrobial agents and chemotherapy,
N Vaisman, and G Koren, and D Goldstein, and G J Canny, and Y K Tan, and S Soldin, and P Pencharz
The effect of high doses of inhaled salbutamol and ipratropium bromide in patients with stable cystic fibrosis.
September 1993, Chest,
N Vaisman, and G Koren, and D Goldstein, and G J Canny, and Y K Tan, and S Soldin, and P Pencharz
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
January 1999, The New England journal of medicine,
N Vaisman, and G Koren, and D Goldstein, and G J Canny, and Y K Tan, and S Soldin, and P Pencharz
AZD5634, an inhaled ENaC inhibitor, in healthy subjects and patients with cystic fibrosis.
July 2022, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,
N Vaisman, and G Koren, and D Goldstein, and G J Canny, and Y K Tan, and S Soldin, and P Pencharz
Intravenous versus inhaled salbutamol.
February 1978, Lancet (London, England),
Copied contents to your clipboard!